Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 75

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 75
---
-interest bearing and shall be due and payable upon the closing
of the Company’s initial Business Combination or upon the Company’s dissolution, whichever occurs first. During the period
from May 23, 2024 (inception) through December 31, 2024, the Company received funds totaling approximately $1,700,000 from various investors
on behalf of the Sponsor. These monies represent advances paid to the Sponsor for purchase of Founder Shares upon successful completion
of the Initial Public Offering. The monies were received on behalf of the Sponsor and deposited into the Company’s bank account
instead of the Sponsor’s bank account. During the period from May 23, 2024 (inception) through December 31, 2024, the Company repaid
approximately $1,200,000 of the balance due to the Sponsor related to investments it had received on behalf of the Sponsor, resulting
in a balance of approximately $500,000 due to the Sponsor, which is accounted for as part of the promissory note amount on the unaudited
balance sheets. In conjunction with the Initial Public Offering $900,000 was repaid to the Sponsor, $204,000 in deferred offering costs
were paid by the Sponsor and $94,574 in expenses were paid by the Sponsor. As of September 30, 2025 and December 31, 2024, there was
$0 and $662,324, respectively, outstanding under the Promissory Note.

Advisory
Services

The
Company received advisory services from an uncompensated related party advisor, husband to the CEO of the Company (the “Advisor”).
The role of such advisor is to assist in the day-to-day transactions of the Company.

CFO
Agreement

Effective
July 1, 2024, the Company’s CFO has a consulting agreement with the Company. For the three and nine months ended September 30,
2025, the Company has incurred $8,825 and $22,764 of expense reported in general and administrative costs on the unaudited statement
of operations, respectively. As of September 30, 2025 and December 30, 2024, $20,000 and $0, respectively, was paid to the Advisor.
As of September 30, 2025 and December 31, 2024, $0 and $1,300 is included in accounts payable and accrued expenses on the balance
sheets.

Related
Party Loans

In